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Abstract
Background: Retrograde transport of several transmembrane proteins from endosomes to the trans-Golgi network
(TGN) occurs via Rab 5-containing endosomes, mediated by clathrin and the recently characterized retromer
complex. This complex and one of its putative sorting receptor components, SorLA, were reported to be
associated to late onset Alzheimer’s disease (AD). The pathogenesis of this neurodegenerative disorder is still
elusive, although accumulation of amyloidogenic Abeta is a hallmark. This peptide is generated from the sucessive
b- and g- secretase proteolysis of the Alzheimer’s amyloid precursor protein (APP), events which are associated with
endocytic pathway compartments. Therefore, APP targeting and time of residence in endosomes would be
predicted to modulate Abeta levels. However, the formation of an APP- and retromer-containing protein complex
with potential functions in retrieval of APP from the endosome to the TGN had, to date, not been demonstrated
directly. Further, the motif(s) in APP that regulate its sorting to the TGN have not been characterized.
Results: Through the use of APP-GFP constructs, we show that APP containing endocytic vesicles targeted for the
TGN, are also immunoreactive for clathrin-, Rab 5- and VPS35. Further, they frequently generate protruding tubules
near the TGN, supporting an association with a retromer-mediated pathway. Importantly, we show for the first
time, that mimicking APP phosphorylation at S655, within the APP 653YTSI656 basolateral motif, enhances APP
retrieval via a retromer-mediated process. The phosphomimetic APP S655E displays decreased APP lysosomal
targeting, enhanced mature half-life, and decreased tendency towards Abeta production. VPS35 downregulation
impairs the phosphorylation dependent APP retrieval to the TGN, and decreases APP half-life.
Conclusions: We reported for the first time the importance of APP phosphorylation on S655 in regulating its
retromer-mediated sorting to the TGN or lysosomes. Significantly, the data are consistent with known interactions
involving the retromer, SorLA and APP. Further, these findings add to our understanding of APP targeting and
potentially contribute to our knowledge of sporadic AD pathogenesis representing putative new targets for AD
therapeutic strategies.
Background
Alzheimer’s disease (AD) is a multifactorial disorder,
with various contributing factors including genetic pre-
disposition and anomalous protein trafficking [1-4]. All
AD forms present characteristic extracellular amyloid
plaques, whose main protein constituent is the 4 kD
amyloidogenic Abeta (reviewed in [5]). This peptide is
generated by two consecutive proteolytic cleavages of its
precursor, the Alzheimer’s amyloid precursor protein
(APP), and is constitutively produced and secreted at
low levels during APP trafficking [6,7].
APP traffic is tightly regulated and the protein is
cleaved by specific proteases. APP follows the constitu-
tive secretory pathway, being N-glycosylated in the
* Correspondence: odetecs@ua.pt
1Neuroscience, Centre for Cell Biology, Health Sciences Department SACS,
University of Aveiro, Aveiro 3810, Portugal
Full list of author information is available at the end of the article
Vieira et al. Molecular Neurodegeneration 2010, 5:40
http://www.molecularneurodegeneration.com/content/5/1/40
© 2010 Vieira et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.endoplasmic reticulum (ER) and further O-glycosylated
(maturation) in the Golgi, where it is highly abundant.
APP can be packaged into secretory vesicles in the trans
Golgi network (TGN) and delivered to the plasma mem-
brane (PM). Cell surface APP may be cleaved to sAPP
or reinternalized into the endocytic pathway [4,8,9].
During this trafficking, full length APP is cleaved to
proteolytic fragments including sAPP (soluble APPa,
soluble APPb), Abeta, p3, and the APP intracellular
C-terminal domain (AICD), with physiological and/or
pathological relevance [10]. The initial cleavage of APP
is executed either by a- (ADAM 10 and/or 17) [11] or
b-secretase (BACE-1) [12], producing a-o rb-soluble
APP (a/bsAPP), respectively, and a membrane-bound
C-terminal fragment (a/bCTF) (reviewed in [10]). CTFs
undergo further cleavages by the g-secretase complex to
produce p3 (from aCTF) or Abeta (from bCTF), along
with the ~50 amino acid AICD fragment [13,14]. The
majority of Abeta production is believed to occur at the
TGN and endocytic vesicles [2,15,16] and dysfunctions
in the endosomal-lysosomal pathways have been
reported in AD and are likely to be associated with AD
pathology [17-20].
Sorting and targeting of APP upon endocytosis
appears to be critically important in Abeta production
and in AD etiology. In fact, the decreased levels and
polymorphisms (particularly those exhibiting lower
expression levels) of the APP-binding and sorting pro-
tein SorLA were associated with AD and mild cognitive
impairment [21-23]. Decreased SorLA levels were asso-
ciated with sporadic but not familial AD [24]. The neu-
ron-enriched SorLA belongs to the mammalian family
of vacuolar protein sorting 10 (VPS10)-containing pro-
teins [25] and, like Sortilin (another member of this
family), acts as a retromer-binding receptor [21,26,27].
The retromer is a multi-subunit complex that regulates
endosome-to-TGN sorting and transport of transmem-
branar proteins, such as the mannose 6-phosphate recep-
tor (MPR) in mammals and VPS10 in S. cerevisiae [[28],
reviewed in [29,30]]. The endosomal-to-TGN retrieval of
several proteins was recently found to involve the retro-
mer complex [31] and intermediate clathrin-coated endo-
cytic vesicles that carry the early endosomal Rab5 marker
[32,33]. A late step of retromer-dependent vesicular
tubulation is necessary for the sorting of proteins away
from endosomes. The retromer complex consists of two
sorting nexin subunits and a cargo-recognition trimer
(VPS26, VPS29, VPS35) [reviewed in [34,35]]. Several
findings indicate that dysfunctional retromer complexes
can be related to AD pathology, with the components
VPS35 and VPS36, being found deficient in sporadic AD
brains [reviewed in [28,36,37]]. Further, as for SorLA,
modulation of the retromer components inversely corre-
lates with Abeta levels [36,37].
Recently some authors have hypothesized that these
correlations most probably occur via retromer and
SorLA-dependent APP recycling between the endocytic
compartment and the TGN [4]. Although strong experi-
mental evidence already supports a role for SorLA in
APP recycling and APP processing [21,27,38,39], retro-
mer-dependent APP retrograde traffic from the endo-
some to the TGN has not been directly demonstrated to
date. In the work here described, we address APP sig-
nals that mediate its TGN retrieval in order to better
characterize this trafficking route. Clues are evident in
the retromer-mediated Golgi retrieval of Sortilin,
CIMPR (cation-independent mannose 6-phosphate
receptor) and SMAP2 (an ARF GTPase-activating pro-
tein) proteins. Trafficking of the latter was shown to
involve the clathrin AP-1 adaptor and an YXXj target-
ing signal in the cytoplasmic tail of the cargo [40-42].
The latter is a known basolateral sorting signal (where ×
is any residue, and j is an aliphatic Leu or Ile or an aro-
matic amino acid). AP-1 and YXXj have been related to
protein traffic between endosomes and TGN, in both
directions. APP possesses such an YXXj sorting signal,
653YTSI
656 (human APP695 isoform numbering), respon-
sible for AP-1 binding and mediating APP basolateral
sorting [43]. Phosphorylation within this sorting motif
appears to modulate this trafficking, and we have
recently reported that mimicking phosphorylation at the
serine 655 residue (S655, APP695 numbering) enhances
APP secretory traffic and increases sAPP production by
the alpha-secretase pathway[ 4 4 ] .I nt h ep r e s e n tm a n u -
script, we describe the endosome-TGN recycling path-
way taken by APP. All the results are consistent with a
model of retromer-mediated APP retrieval to the TGN,
which is enhanced by direct APP phosphorylation at its
cytoplasmic S655 residue.
Results
Endocytosed APP is recycled to the TGN and sorted into
tubular structures
COS-7 cells transfected with Wt APP-GFP at expression
levels similar to endogenous APP, were treated with
cycloheximide (CHX) for 3 h, thus blocking “de novo”
protein synthesis and permitting us to monitor turnover
of a specific APP-GFP population [45,46]. APP-GFP
endocytosis was analyzed by co-localization with three
proteins that are associated with the endocytic route
(Fig. 1). In the first panel (Fig. 1a), Texas red-conjugated
transferrin molecules were added to the medium, and
endocytosis was allowed to occur for 15 min at 37°C.
A high number of APP-GFP green vesicles could be
observed throughout the cytoplasm of transfected cells,
part of this population co-localizes with transferrin-posi-
tive vesicles (yellow/orange vesicles, Fig. 1a ROI), con-
firming the co-endocytosis of APP-GFP together with
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population is therefore travelling via the endocytic path-
way. This was further confirmed by co-localization of
APP-GFP with Rab5 and Rab7 by immunocytochemistry
procedures (Fig. 1b and 1c). These are two small
GTPases of the Rab family that are associated with early
and late endosomal vesicles, respectively. A significant
number of APP-GFP/Rab5 and APP-GFP/Rab7 endocy-
tic vesicles could also be detected (Fig. 1b and 1c,
respectively, yellow/orange vesicles in ROIs, asterisks in
the histograms). Quantitative analyses, using the Zeiss
confocal software, were performed, and co-localization
of endocytic markers and APP was confirmed (Table 1).
Of note, the eGFP protein alone is distributed through
the nucleus and cytoplasm, but is not targeted to cyto-
plasmic vesicles [47].
The fate of endocytosed APP, in terms of retrograde
retrieval, was subsequently analyzed making use of the
APP-GFP construct and an antibody uptake assay. Wt
APP-GFP expressing cells were incubated in ice-cold
conditions in the presence of an antibody against the
APP ectodomain (22C11). This antibody was raised
against an APP ~50 aa N-terminal epitope, and
Figure 1 APP-GFP traverses the endocytic pathway. (a) COS-7 cells transfected with Wt APP-GFP were exposed for 3 h to the protein
synthesis inhibitor CHX and incubated in the last 15 min with Texas Red-conjugated transferring. Co-localization (yellow/orange fluorescence
vesicles) between transferrin (Texas red endocytic vesicles) and APP-GFP green cytoplasmic vesicles can be observed (Overlay panel).
Immunocytochemistry analysis with (b) an early (Rab 5) and (c) late (Rab 7) endosomal markers were also performed and co-localization
observed. ROI, region of interest, denotes APP-GFP co-localizing endocytic vesicles. Bar, 10 μm. Fluorescence intensity profiles are also presented,
representing the voxels through the white arrowed lines indicated in the ROI overlay images; asterisks denote co-localizing vesicles.
A microphotograph of the eGFP protein is presented as a negative control, GFP alone is distributed through the nucleus and cytoplasm, but is
not targeted to cytoplasmic vesicles.
Table 1 Co-localization of the Wt APP-GFP protein with
the endocytic markers Transferrin, Rab 5, and Rab 7
Wt APP-GFP co-localization coefficients (%)
In cytoplasmic
vesicles
In cell (cytoplasmic vesicles and
Golgi)
Transferrin 18.8 ± 0.3 34.5 ± 2.4
Rab 5 19.5 ± 0.7 30.3 ± 2.4
Rab 7 15.2 ± 1.2 36.6 ± 2.0
The co-localization coefficients presented reflect the percentage of APP-GFP
pixels co-localizing with Transferrin, Rab 5 or Rab 7 pixels, respectively, in
cytoplasmic vesicles only or in total cell. Total number of pixels in the APP-
GFP channel is taken as 100%. Values are mean ± SEM (n=10).
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green fluorescent C-terminal peptides. Surface labeling
of APP was achieved with 22C11 and endocytosis
was monitored by tracking 22C11 uptake/APP-GFP co-
localizing vesicles. Fig. 2, shows images taken at 0 min
at 37°C, (cell surface focus plane), and subsequent
images taken upon 15 min incubation at 37°C (focus
plane through the Golgi), whereupon endocytosis had
been allowed to proceed. By the end of the 15 min per-
iod, some of the co-localizing red 22C11/APP-GFP
green vesicles, corresponding to full-length endocytosed
APP-GFP, could be observed at the TGN area (Fig. 2,
15 min, white vesicles). The Golgi is the major subcellu-
lar site of APP enrichment [48], being easily identified
as the intense juxtanuclear green fluorescent structure
(Fig. 2, boxed area and [49]). Some of the 22C11 stain-
ing was confirmed to localize at the trans and/or medial
Golgi regions, by co-transfection with an enhanced cyan
fluorescence protein-Golgi (ECFP-Golgi) construct car-
rying a galactosyltransferase signal targeting it to the
trans and medial-Golgi. Further morphologic analysis of
these 22C11-positive vesicles at the TGN revealed tubu-
lar protuberances emerging from several of the vesicles,
resembling the characteristic retromer-induced sorting
tubules (Fig. 2, arrows in ROI). Of note, some of these
tubular structures were also positive for the ECFP-Golgi
construct, being co-transported with APP back to the
TGN. This has been reported to occur in a retromer-
dependent manner for several proteins e.g. TGN38/46
or furin that were used as TGN markers [30]. Thus it is
clear that part of the endocytosed APP population is
recycled to the TGN and sorted into tubular structures,
suggesting a retromer-mediated pathway.
APP is retrieved from endosome to TGN through clathrin
and Rab5-positive vesicles
Endocytosed APP-GFP vesicles were further analyzed for
their co-localization with protein markers (Rab5 and cla-
thrin) known to be present in intermediate endosomes
destined for TGN retrieval via the retromer complex
(Fig. 3). Surface internalized Wt APP-GFP (green APP-
GFP/blue 22C11 co-localizing vesicles) could be observed
Figure 2 A pool of endocytic APP-GFP is targeted to the TGN. Wt APP-GFP at COS-7 cell surface was labelled by incubating cells with the
22C11 anti-APP ectodomain antibody ("22C11 Uptake”, Texas red staining) at 4°C. At 0 min, 22C11 staining is maintained at the cell surface
(microphotographs taken at the plasma membrane focal plane). Following 15 min at 37°C, part of the 22C11 population can be observed at
vesicular structures around the Golgi (arrowhead; microphotographs taken at the Golgi focal plane). Endocytic 22C11/APP-GFP targeting to the
TGN was confirmed by co-localization with a pECFP-Golgi construct ("CFP-Golgi”, blue fluorescence), a construct targeted to the trans and medial
region of the Golgi. Of note, since the CFP-Golgi fusion protein has a weak blue fluorescence, it is virtually non-visible at the plasma membrane
focal plane. ROI - region of interest, 2.0-fold magnified. Several white vesicles, denoting 22C11/APP-GFP/CFP-Golgi co-localization, can be
observed at the TGN (arrows in ROIs), A tubular morphology can be depicted for some of these vesicles in the ROIs. Bar, 10 μm.
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Page 4 of 21Figure 3 Endocytosed APP is present in Clathrin and Rab 5-positive vesicles tubulating vesicles. The 22C11 uptake assay (Alexa350 blue
staining) was repeated in COS-7 cells for further characterization of the vesicles retrieving endocytosed APP-GFP to the TGN.
Immunocytochemistry analysis using antibodies against (A) clathrin and (B) Rab 5 (Texas red staining) confirmed the presence of these proteins
in APP-GFP endocytic vesicles. ROI, region of interest, 1.7- and 2.0-fold magnified, respectively. Arrows in ROIs depict APP tubulating endosomes,
further magnified. While 22C11/APP-GFP and clathrin were observed to be sorted from the vacuole to the emerging tubule, Rab 5 appears to be
maintained in the vacuole. Bar, 10 μm. (C) confocal quantitative analysis of the degree of co-localization between Wt APP-GPP and uptaken
22C11 with clathrin and Rab-5. Values are mean ± SEM, n = 20 cells.
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whitish vesicles (white arrows in Fig. 3a and 3b ROIs,
respectively). Co-localization quantitative analysis
was performed (Fig. 3c), rendering the following results:
23.2 ± 2.1 and 29.2 ± 0.7% for Wt APP-GFP co-localiza-
tion with Clathrin and Rab 5, respectively, increasing to
40.0 ± 1.3 and 35.5 ± 0,9% co-localization with uptaken
2 2 C 1 1a n t i b o d yf o rt h es a m ep r o t e i n s .M o r e o v e r ,t h e
previously observed protruding tubules, emerging from
the donor vesicle, could also be detected (Fig. 3a and b,
depicted structure in ROIs). All our data are consistent
with a retromer-mediated TGN retrieval for APP. To
note, the definition at this photonic level is not very high,
and higher resolution can only be obtained with electro-
nic devices as has been observed by other authors
[32,33]. Detailed evaluation reveals that the APP-GFP
staining (green/blue co-localization) is present in the
donor vesicle and in the emerging tubule (Fig. 3a and 3b,
white depicted structure in ROI). The same appears to
occur with the clathrin staining that, as far as can be
observed, was also present in both parts of the structure
(Fig. 3a, white depicted structure in ROI), in accordance
with a potential role in assisting retromer in membrane
curvature [33]. However, we could not observe the same
for the Rab 5 staining. This appears to be only present at
the donor pre-tubular vesicle (Fig. 3b, depicted structure
in ROI), as reported for other early endosome proteins
such as the transferrin receptor or EEA1 [33]. Further
evidence for an APP retromer-mediated TGN retrieval
was obtained by partially blocking retrograde transport
to the TGN by incubating at 19.5°C [32,33]. Following 15
min at 19.5°C, co-localizing APP-GFP/endocytosed
22C11/clathrin white vesicles were found more distribu-
ted throughout the cytoplasm, there was obvious co-loca-
lization among the three stains and a marked decrease in
the number of tubular structures detected (additional file
1). These changes are consistent with events associated
with a temperature block as previously reported [32,33].
PDBu enhances APP and VPS35 co-localization at the
Golgi
The above results indicate that endocytosed APP is
retrieved to the TGN via a trafficking route involving the
retromer, of which VPS35 is a component. We have
addressed the co-localization of these two proteins and
alterations in response to PKC activation. In fact, APP and
VPS35 co-localize to vesicular structures throughout the
cell (additional file 2). Phorbol esters are known to alter
APP processing [50], and interestingly, PKC activation
resulted in altered APP/VPS35 distribution, increasing co-
localization around the Golgi area (additional file 2). Pro-
tein kinase C (PKC) is known to phosphorylate APP only
at S655, potentially enhancing the exit of APP-containing
vesicles [44,50,51]. Mechanistically, we propose that APP
phosphorylation within the sorting motif
653YTSI
656 may
be involved both in protein sorting from and to the TGN,
as seen for the sortilin, which has the YSVL sequence
[42,43]. Hence, APP-GFP S655 phosphomutants were
employed to determine the influence of S655 phosphoryla-
tion on APP endosomal traffic and related processing.
Mimicking S655 phosphorylation results in enhanced
mature APP half-life
Cells were transfected with APP-GFP cDNAs carrying
phosphomutations at S655 (dephosphomimetic S655A
and phosphomimetic S655E) and the levels of APP-GFP
proteins were monitored with time of CHX incubation.
Immunoblotting analysis using the anti-APP 22C11 anti-
body (Fig. 4A) revealed two bands migrating at the
expected molecular weights for the APP-GFP fusion
proteins, band a (~136 kD) and band b (~145 kD), cor-
responding to the immature and mature APP-GFP spe-
cies, respectively [46]. APP-GFP proteins matured
similarly to endogenous APP [44], and APP-GFP
maturation was unchanged by S655 phosphomutations;
35.0 ± 3.3% for Wt, 32.8 ± 2.7% for S655A and 34.0 ±
4.0% for S655E (calculated as the % of mature APP-GFP
relative to total APP-GFP levels, at 0 h of CHX expo-
sure). A representative profile of APP-GFP C-terminal
peptides with CHX is presented in additional file 3.
These peptides accounted for 25-50% of the GFP popu-
lation at the 2h-3 h in CHX time interval.
The levels of the APP-GFP species with time in CHX
were subsequently quantified and expressed as percen-
tages of initial levels at time 0 h CHX (Fig. 4A). The
rates of immature APP-GFP protein turnover were
mainly found unaltered (Fig. 4A, left graph). All imma-
ture APP-GFP proteins (Wt, S655A, S655E) rapidly
decreased with time in CHX and reached the same end
point (~20% of initial levels at 5 h). Slight delays in
immature S655E disappearance are most probably of no
physiological significance, since immature APP is not
normally phosphorylated at S655 [52]. In contrast, com-
parison of the mature APP-GFP time courses revealed
differences in the turnover rates of the mature S655
mutants (Fig. 4A, right graph). Upon 5 h of CHX expo-
sure, levels of Wt and S655A proteins decreased to 20%
of initial levels, while levels of the S655E mutant only
decreased to 40% (Fig. 4A, right graph). Additionally,
the Wt had an initial positive slope (0-1 h) that was
considerably augmented and sustained over time for the
S655E mutant, but absent for S655A. The absence of
this initial peak for S655A suggests that this form is
more readily available for catabolism. In sharp contrast,
the mature S655E levels decreased below 100% only
after 2 and 3 h. Mature APP-GFP half-lives were subse-
quently calculated as 2.46 ± 0.16 h for the Wt, 2.12 ±
0.08 h for the S655A, and 5.56 ± 0.41 h (p <0 . 0 0 1v s
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Page 6 of 21Figure 4 S655 APP phosphomutants exhibit differential cellular catabolism. (A) Wt and S655 phosphomutants turnover rates in COS-7 cells.
Upper panel: Immunoblot analysis of APP-GFP transfected cells lysates using the anti-APP antibody 22C11. Bands a and b, immature (N-
glycosylated) and mature (N- and O-glycosylated) APP-GFP forms, respectively, migrating above endogenous APP forms of ~115 kD and ~109 kD
(potentially immature APP751/770 and APP695, respectively). APP-GFP bands identity was further confirmed using an anti-GFP antibody (data not
shown). Lower panel: plotted data of the levels of immature (left graph) and mature (right graph) APP-GFP, expressed as percentage of OD values
at 0 h in CHX. Values are mean ± SEM (n = 6). Statistical significance symbols: (*), S655 phosphomutants vs. Wt; (
+), S655A vs. S655E; statistical
significance levels are presented as (*/
+) for p ≤ 0.05; (
++), for p < 0.01; and (***/
+++) for p < 0.001. (B) S655A is preferentially delivered to lysosomes.
The targeting of Wt and S655 phosphomutants (green vesicles) to lysosomes was analysed by co-localization with the lysosomal marker cathepsin
D ("Cat D”, red vesicles). Arrows indicate APP-GFP-containing lysosomes (green/red co-localizing vesicles). Bar, 10 μm. (C) Alterations in the mature
S655A and S655E turnover upon inhibition of lysosomal hydrolases with 50 μM chloroquine (CQ). Left: Immunoblot analysis of transfected cells
lysates using the anti-GFP antibody JL-8. Right: mature S655A and S655E (band b) levels were quantified and data plotted as percentages of OD
values at 0 h in CHX. Values are mean ± SEM (n = 3); (
#), statistical significance of p ≤ 0.05 for CQ plus vs control data.
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tigated whether S655-dependent rates of catabolism
could be due to divergent sorting fates upon APP endo-
cytosis, i.e., targeting to the TGN or to lysosomes.
The dephosphomimetic S655A mutant is preferentially
targeted for lysosomal degradation
Contrasting half-lives for the mature forms of S655
APP-GFP phosphomutants suggest differences in lysoso-
mal degradation. The influence of S655 phosphorylation
on APP lysosomal targeting was therefore analyzed by
co-localization with the lysosomal marker cathepsin D
(Cat D). APP-GFP expressing cells presented a typical
subcellular distribution of Cat D (red staining) in small
cytoplasmic vesicles, enriched near the Golgi area (Fig.
4B). The number of APP-GFP/Cat D co-localizing vesi-
cles was low, ranging from 2 to 20 per cell, when com-
pared with an average number of ~100 APP-GFP
endocytic vesicles per cell (Fig. 1). These values are not
surprising, given that APP is primarily detected in lyso-
somes when lysosomal proteolysis is inhibited [49,53].
Transfected cells were thus monitored for the extent of
APP-GFP/Cat D co-localization (Table 2). The percen-
tage of green/red co-localizing vesicles relative to total
APP-GFP green cytoplasmic vesicles was scored (Table
2, “Vesicular co-loc.”), and microphotographs were ana-
lyzed by a Zeiss confocal software to determine APP-
GFP/Cat D co-localization coefficients (Table 2, “Co-loc.
coefficient”). Both approaches rendered similar values
and confirmed the visual observation that lysosomal tar-
geting was diminished in the S655E mutant, whereas in
the S655A mutant APP-GFP co-localization with CatD
was enhanced. Consequently, cells expressing S655A
a n dS 6 5 5 Ew e r ee x p o s e dt oc h l o r o q u i n e( C Q ) ,ad r u g
that neutralizes lysosomal pH, thereby partially inhibit-
ing mature APP lysosomal degradation [49]. CQ was
able to shift the basal pattern of mature S655A catabo-
lism to resemble a S655E-like pattern (compare Fig. 4C
graphs), while the mature S655E profile only suffered
slight increases upon CQ treatment. This clearly
associates S655 phosphorylation state with APP-GFP
catabolism via lysosomal degradation.
S655 phosphorylation is a targeting signal for APP
retrieval to the TGN
The half-life of mature S655E was doubled, consistent
with it being sorted away from lysosomal degradation.
Enhanced S655E TGN retrieval supports its deviation
from the default lysosomal pathway, resulting in
increased recycling. Therefore the antibody uptake assay
(Fig. 2 and 3) was repeated for all APP-GFP constructs
(Wt, S655A and S655E) and the dynamics of endocytic
APP retrieval to the TGN were monitored with time at
37°C (Fig. 5). Epifluorescence microscopy was first used
for an overview of all the APP-GFP endocytic vesicles,
and confocal microscopy was used for quantification
analysis of targeting to the Golgi area.
As previously observed (Fig. 2), at 0 min, a strong
22C11 antibody red staining co-localizing to all APP-
GFP proteins could be observed at the cell surface (Fig.
5 a ,0m i n ) .U p o n1 5m i no fe n d o c y t o s i s ,d i f f e r e n c e s
could be detected in the location of the APP-GFP posi-
tive endocytic vesicles, depending on the construct
being expressed. A semi-quantitative approach was used
to study retromer-mediated recycling [54]. At 15 min at
37°C, some of the endocytosed Wt and S655E APP-GFP
vesicles were found near or at the Golgi area, but more
so for the S655E protein (Fig. 5a, 15 min). Of note, the
main fluorescent perinuclear structure in APP-GFP
expressing cells was confirmed as the Golgi area using
the ECFP-Golgi construct, in APP-GFP/ECFP-Golgi co-
transfected cells upon 30 min 22C11 uptake (Fig. 5b).
This distribution occurred in 50% of S655E-expressing
cells, but only in 30% of Wt-expressing cells. In con-
trast, co-localization of endocytic S655A vesicles at the
Golgi area was largely undetectable (only visible in 7%
of S655A-expressing cells), and mainly remained ran-
domly distributed throughout the cells’ cytoplasm (Fig.
5a, 15 min). By 30 min at 37°C, 22C11/APP-GFP endo-
cytic vesicles co-localizing at the Golgi area increased to
70% of S655E-expressing cells, compared to 50% for Wt
and 40% for S655A. Furthermore, percentage co-locali-
zation of endocytosed APP (22C11 Uptake) with the
APP-GFP population at the Golgi area was determined
for each of the three proteins using the Zeiss confocal
software (Fig. 5c). Results for the three APP-GFP pro-
teins supported previous observations, namely that the
phosphomimicking S655E undergoes enhanced recy-
cling: 20.3 ± 2.9% for Wt, 5.7 ± 0.8% for S655A, and
39.2 ± 3.9% for S655E (n = 20 cells; p < 0.001 for S655E
data vs Wt or S655A data; p < 0.01 for Wt vs S655A
data).
In order to confirm that we were monitoring endocy-
tosed APP, cell permeabilization was omitted in some
Table 2 Co-localization of the S655 phosphomutants with
the lysosomal marker cathepsin D
Parameters of APP-GFP/Cat D co-localization
APP-GFP % Vesicular co-loc. % Co-loc. coefficient
Wt 5.0 ± 0.5 6.4 ± 0.7
S655A 9.6 ± 0.4***
/+++ 10.2 ± 0.8***
/+++
S655E 3.1 ± 0.3
+++ 3.6 ± 0.0*
/+++
The number of APP-GFP/cathepsin D co-localizing vesicles was scored and
expressed as percentage of APP-GFP-containing vesicles ("Vesicular co-loc.”).
The co-localization coefficients ("Co-loc coefficient”) represent the relative
percentage between the number of APP-GFP/cathepsin D co-localizing pixels
and the total number of pixels of the APP-GFP channel, upon single cell
delimitation. Values are mean ± SEM (n = 20). (*), S655 mutant vs Wt data; (
+),
S655A vs S655E data. *, p < 0.05; ***/
+++, p < 0.001.
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Page 8 of 21Figure 5 S655 phosphorylation is a targeting signal for retrieval of APP to the Golgi. (A) Wt, S655A and S655E APP-GFP at the cell surface
were labelled (0 min) by incubating COS-7 cells with the 22C11 anti-APP ectodomain antibody ("22C11 Uptake”, Texas red staining) at 4°C.
Following 15 and 30 min of incubation at 37°C, the localization of APP-GFP endocytic vesicles (green/red-22C11 co-localizing vesicles) were
monitored. Arrows indicate the Golgi area and APP-GFP/22C11 endocytic vesicles co-localizing to or around the same region. ROI - region of
interest denoting the Golgi area and co-localizing vesicles. (B) The highly green-fluorescent perinuclear structure in APP-GFP transfected cells
was confirmed to be the Golgi in Wt APP-GFP and CFP-Golgi co-transfected cells, upon 30 min of 22C11 uptake. Bar, 10 μm. (C) confocal
quantitative analysis of the degree of co-localization between uptaken 22C11 and the APP-GPP population at the Golgi area at 30 min of
22C11 antibody uptake (AU) at 37°C. Values are mean ± SEM, n = 20 cells. Statistical significance symbols used were: (*) for comparison of
S655 phosphomutant and Wt data; (
+) S655A vs S655E data. Statistical significance levels are presented as (**), for p < 0.01; and (***/
+++), for
p < 0.001.
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Page 9 of 21experiments and, in these conditions, vesicles typical of
endocytosis (as in Fig. 3 and 5, for example) were not
visible, but rather diffuse dot-like staining could be
visualized at the plasma membrane (additional file 4).
S655 phosphorylation dependent APP retrieval to the
TGN is potentially mediated by the retromer complex
All the above data strongly suggest that TGN retrieval of
APP is mediated by the retromer complex in a S655-
phosphorylation state dependent manner. Further data
strengthening this hypothesis arise from co-localization
studies of endocytosed Wt, S655A and S655E with the
retromer protein component VPS35. The latter occurs
endogenously in COS-7 cells [55]. The previous 22C11
antibody uptake assay was used, and the degree of co-
localization between endocytosed APP and VPS35, at a
focal plane crossing the Golgi apparatus, was determined
using the Zeiss confocal software. Microphotographs
(Fig. 6a) show that all three APP-GFP proteins endocy-
tosed co-localize with VPS35-containing vesicles. For
each APP-GFP protein, endocytosis was confirmed given
the co-localization of the blue 22C11 fluorescence and
green APP-GFP fluorescence. Co-localization with the
VPS35 derived red staining was evident throughout the
cytoplasm, but to a higher extent near or at the Golgi
area (Fig.6a). This is clearly indicative of APP-GFP endo-
somal-to-TGN targeting being mediated by the retromer
complex, and consistent with all the above data. Notably,
some of the vesicular structures where the three stainings
co-localize (white structures, circumference drawn by a
black outline in the ROI, Fig.6) have the “tubular bud-
ding” morphology characteristic of retromer-mediated
membrane deformation (see Fig. 6a, arrows in ROI). APP
delivery to the TGN appears to occur through these tub-
ular structures upon the TGN targeting of the APP-con-
taining intermediate endosomes. Further, and of central
importance, a higher co-localization between endocy-
tosed S655E APP-GFP and VPS35 could be easily
observed, in particular when compared to the S655A
mutant that exhibited the lowest degree of co-localization
(Fig. 6a, arrowhead in ROI). The co-localization coeffi-
cients of the APP-GFP population with VPS35 and the
uptaken 22C11 with VPS35 were evaluated for each
APP-GFP protein (Fig. 6b). The results revealed a marked
difference for the S655E mutant. Wt APP-GFP co-
localized with VPS35 by 18.0 ± 0.9%, the S655A mutant
by 13.4 ± 0.4%, while co-localization values for the S655E
doubled to 38.0 ± 1.2% (Fig 6b, grey columns). The
values obtained for the 22C11 uptake and co-localization
with VPS35 were similar (Fig. 6b, black columns), con-
firming that endocytosed full-length APP-GFP proteins
were being monitored.
Together, the data prove a S655 phosphorylation-
enhanced APP TGN retrieval, and strongly suggest this
to be retromer-mediated. The TGN retrieval pathway,
involving SorLA and the retromer, has been inversely
correlated with Abeta production. Therefore, the levels
of Abeta were also analyzed in the 3 h conditioned
media of transfected cells. For each APP-GFP protein,
all the individual Abeta species detected followed similar
fold-increases. Their sum is here presented graphically
(Fig. 6c, lower blot, ‘total Abeta’), upon correction for
holo APP-GFP relative transfection levels (ratio between
APP-GFP levels, each calculated by the sum of bands a
+b in Fig. 6c, upper blot). The differences between
Abeta amounts produced by the APP-GFP proteins
under CHX revealed some differences. However, levels
were very low and difficult to measure reliably (data not
shown). Thus, comparative Abeta production was mea-
sured in 3 h CHX-free media, resulting in less marked
differences due to continuous expression of APP-GFP.
Nonetheless, a tendency towards lower total Abeta pro-
duction for S655E (0.83 ± 0.13 of Wt values) is
observed, consistent with a lower time of residence in
the endosomes for this mutant, due at least in part, to
faster recycling back to the TGN.
APP co-immunoprecipitates with VPS35 and SorLA
To analyze the formation of APP/VPS35 and APP/
SorLA complexes, immunoprecipitation assays were
further conducted. APP, whether endogenous or
expressed as APP-GFP, was found to co-immunopreci-
pitate with endogenous ~95kDa VPS35 (Fig. 7a,b,c).
Although the endogenous signal for VPS35 is weak, it is
clear that APP and VPS35 co-immunoprecipitate (Fig.
7a,b). For comparison purposes, the IP was repeated for
the three Wt/S655A/S655E APP-GFP proteins, and a
higher level of VPS35 was observed to co-IP with S655E
(Fig. 7c), suggesting that S655 phosphorylation enhances
APP binding to the retromer complex. Further, APP-
VPS35 binding may be direct or through SorLA as a
bridging protein. Indeed, when co-expressed in
HEK293T cells, mature APP695 co-immunoprecipitated
with SorLA and mature SorLA co-immunoprecipitated
with APP695 (Fig. 7D). These results agree with previous
studies by [56,57] showing an interaction between APP
and SorLA. Of note, APP and SorLA C-terminal frag-
ments (CTF) did not co-immunoprecipitate, and the
additional negative control, eGFP, also failed to co-
immunoprecipitate with either SorLA or APP.
Downregulation of VPS35 impairs endocytosed APP
retrieval to the TGN
Given the central role proposed for the retromer com-
plex, it became essential to analyze the effects of VPS35
down-regulation on S655E APP-GFP retrieval to the
TGN and on this mutant’s half-life. VPS35 expression
was decreased by means of siRNA transient transfection.
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Page 10 of 21Figure 6 S655 phosphorylation-dependent APP retrieval occurs via VPS35-containing endocytic vesicles. (A) APP-GFP transfected COS-7
cells were subjected to the 15 min 22C11 uptake assay (Alexa350 blue staining) and the co-localization of endocytosed APP-GFP proteins (blue/
green vesicles) with the VPS35 retromer subunit (Texas red staining) was monitored. The Golgi area denotes the highest degree of co-
localization, and a region was magnified for better visualization of the tubulating vesicles (ROI-4.0-fold magnified; arrows point to APP-GFP/
AU22C11/VPS35-positive structures for Wt and S655E, and arrowhead to a S655A APP-GFP-negative, AU22C11/VPS35-positive structure). Some of
the tubulating vesicles for Wt and S655E have been represented schematically with a black line. (B) Co-localization between APP-GFP or 22C11
uptake with VPS35 was quantified using confocal software. Values are mean ± SEM, n = 30 cells. Statistical significance symbols: (*), S655
phosphomutant vs Wt data; (
+), S655A vs S655E data. Statistically significant levels are presented as (**) for p < 0.01; and (***/
+++) for p < 0.001.
(C) Secreted Abeta peptides from 3 h conditioned media of APP-GFP or EGFP vector ("V”) transfected COS-7 cells. Samples were
immunoprecipitated, separated on urea gels and immunostained with mAb 1E8. Upper panel: Immunoblot analysis of cells lysates using the
anti-APP antibody 22C11. Bands a and b, transfected immature and mature APP-GFP forms, respectively. The various Abeta species were
quantified, corrected for the relative respective APP-GFP expression levels (bands a+b), and plotted as fold-increase of total (sum of all species)
Abeta fragments over Wt values (mean ± SEM, n = 3).
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Page 11 of 21VPS35 down-regulation conditions were first optimized,
with the levels of VPS35 expression being the lowest (64
± 4%, n = 6, p < 0.05 vs control data) for 5 nM of
VPS35 siRNAs transfection upon 24 h of expression,
while 10 nM resulted in a similar decrease (Fig. 8A). Of
note, transfection of 5 or 10 nM of VPS35 siRNAs
resulted in a decrease of sAPP secretion into the med-
ium to ~80% of control levels (data not shown).
The 22C11 antibody uptake assay was subsequently
repeated in COS-7 cells transiently co-transfected with the
S 6 5 5 EA P P - G F Pc D N Aa n d5n Mo ft h eV P S 3 5s i R N A s
for 24 h, followed by 2h30 h in CHX (Fig. 8B). A clear
decrease in the S655E APP-GFP signal was visible in cells
where VPS35 expression (red labeling) was down-regu-
lated (Fig. 8B.II siRNA VPS35). Further, the APP-GFP sig-
nal was found in cytoplasmic vesicles and was absent from
the Golgi of the majority of these cells (65.0 ± 8.0% of the
population). This is in contrast with what occurs in
control cells (Fig. 8B.I), where the S655E APP-GFP signal
was clearly visible at the Golgi of 83.0 ± 3.7% of the cells
(p < 0.01, n = 3 independent experiments where 30-100
cells were scored). Low levels of endocytosed APP (AU
22C11, blue staining) were observed in cells where VPS35
was down-regulated, most probably resulting from the
observed decrease in APP-GFP levels. Most importantly,
in ~90% of the siRNA VPS35 transfected cells, the endocy-
tosed 22C11 vesicles were found diffusely distributed
throughout the cytoplasm (Fig. 8B, 22C11 uptake), in con-
trast with the normal localization around and at the TGN
in control cells (Fig. 8B.I, 22C11 uptake). Noticeably, simi-
lar 22C11 vesicular distribution was also observed in the
smaller percentage of the population (35.0 ± 8.0%) where
APP-GFP was still visible at the Golgi (Fig. 8B.III). Thus,
down-regulation of cellular VPS35 levels resulted in less
S655E APP-GFP at the Golgi and impaired APP retrieval
from the endosome to the TGN.
Figure 7 Co-immunoprecipitation of APP, VPS35 and SorLA in COS-7 and HEK293 cells. (A) Endogenous APP and VPS35 were co-
immunoprecipitated in COS-7 cells using the anti-APP N-terminus 22C11 and the anti-VPS35 antibodies (aVPS35). Negative controls (C) were
performed by immunoprecipitating cells with the same secondary antibodies, sepharose- (IP VPS35 control) and agarose- (IP 22C11) linked,
respectively. (B) Transfected Wt APP-GFP and endogenous VPS35 co-immunoprecipitate from COS-7 cells using the indicated antibodies (Ab). (C)
Transfected Wt, S655A and S655E APP-GFP were immunoprecipitated in COS-7 cells with the anti-GFP antibody, and the co-immunoprecipitated
endogenous VPS35 forms were detected with an anti-VPS35 antibody. Asterisk (*), non-specific IgGs bands (IgGs raised in goat) of the IP
samples. Non-transfected cells (C(nt)) submitted to the same IP procedures (incubated with primary and agarose-linked secondary antibodies)
were used as control in (B) and (C). (D) HEK293T cells were cotransfected with SorLA cDNA, APP695 and eGFP (transfection control).
Immunoprecipitation was performed using antibodies raised against the C-terminus of APP (369), the N-terminus of SorLA (aSorLA) or using pre-
immune serum as negative controls (C). Immunoprecipitation and co-immunoprecipitation were detected by western blot (WB) using the anti-
APP 369 antibody and an anti-SorLA C-terminus antibody (aSorLA C-term). Immunoblot analysis included GFP as an additional negative control.
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Page 12 of 21Figure 8 VPS35 down-regulation impairs S655E APP-GFP retrieval to the TGN and decreases its turnover rate. (A) Left:
Immunodetection of VPS35 levels in COS-7 cells co-transfected with N1 EGFP and several concentrations of anti-VPS35 siRNAs for 24 h. Tubulin
was probed as a control. Right: Quantification of VPS35 levels, plotted as percentages of control conditions (cells only transfected with N1 EGFP).
Values are mean ± SEM (n = 2-6); (#), statistical significance of p ≤ 0.05 for siRNA VPS35 vs control data. (B) The 15 min 22C11 antibody uptake
assay (Alexa350 blue staining) was applied to monitor S655E APP-GFP protein retrieval from the endosome to the TGN upon COS-7 cells pre-
incubation with 5nM VPS35 siRNAs for 24 h to downregulate VPS35 (Texas red staining). (B.I) Control: cells only transfected with S655E APP-GFP.
(B.II - B.III) siRNA VPS35: cells co-transfected with S655E APP-GFP and VPS35 siRNAs; in the majority of the population, the APP-GFP signal at the
Golgi was not visible (B.II), while in a minor percentage of cells APP-GFP was still visible at the Golgi (B.III). Bar, 10 μm. (C) S655E APP-GFP
turnover rate in CHX upon cells pre-incubation with 5nM VPS35 siRNAs for 24 h. Left: Immunoblot analysis of COS-7 transfected cells lysates
using the anti-APP 22C11 and anti-tubulin antibodies. Bands a and b, immature and mature APP-GFP forms, respectively, migrating above
endogenous APP forms. Right: mature S655E levels were quantified and plotted as percentages of OD values at 0 h in CHX. Values are mean ±
SEM (n = 3); (#), statistical significance of p ≤ 0.05 for siRNA VPS35 plus vs control data.
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of the S655E APP-GFP mature form was also addressed
(Fig. 8C), using the approach discussed above. Strikingly,
cell pre-incubation with VPS35 siRNAs for 24 h resulted
in both an increase in APP-GFP levels (0 h in CHX) and
in an increase in the APP-GFP and endogenous APP
turnover rates. Indeed, VPS35 down-regulation induced
a shift in the basal pattern of mature S655E catabolism
towards a more S655A-like pattern (compare Fig. 8C
and 4A graphs). Indeed, the typical initial (0-1 h) posi-
tive slope in the S655E APP-GFP profile is completely
abolished when VPS35 is downregulated, and mature
S655E APP-GFP half-life decreased 2.1 ± 0.3 fold.
Further, the diminished levels of APP-GFP at 2-3 h
CHX are in agreement with the observed lower APP-
GFP and 22C11 uptake signals observed in Fig. 8B.
These results conclusively associate the retromer com-
plex with APP-GFP catabolism and its retrieval to the
TGN upon its endocytosis.
Discussion
The time of residence associated with APP traversing
the endosomal pathway is critical to its processing and
appears to correlate with Abeta levels and AD pathogen-
esis [28,58,59]. Endosomes are known sorting stations,
crucial to understanding AD [21-24,37], but the molecu-
lar mechanisms underlying endosomal APP sorting and
trafficking are not clearly defined [4,28]. In the work
here described, we observed that endocytosed APP
molecules can be sorted for rapid retrieval to the TGN,
in a retromer-mediated manner. Although we have
found vesicle tubulation outside the TGN vicinity, our
results suggest that tubulation occurs to a higher extent
in APP-containing intermediate endosomes near the
TGN (Fig. 2). Hence, the nascent tubule appears to be
directly responsible for the delivery of retrieved APP
cargo to the TGN. As previously reported, at the protein
level, the intermediate endosomes are positive for cla-
thrin and for the early endocytic marker Rab5, although
with apparent minor differences in their distribution
(Fig. 3). We have also shown that, at least at the photo-
nic level of resolution used, Rab5 appears not to be
sorted to the emerging tubule, while clathrin was pre-
sent in this nascent structure (ROIs in Fig. 3). Other
early endosome markers, such as EEA1 [33], present a
distribution similar to that observed by us for Rab5 in
the intermediate endosomes destined for the TGN. The
co-localization of APP with a retromer component
related to cargo recognition, VPS35, strongly suggested
it as a retromer-mediated pathway.
Since components of the retromer-mediated pathway
and endocytic APP fate have been associated with AD
pathology, we found it particularly important to address
the regulatory signals determining retrieval of APP to
the TGN. Transmembrane protein trafficking in the
post-TGN membrane system may contain several
sorting signals regulating protein transport between the
various compartments [41]. For example, CIMPR under-
goes retromer-dependent retrieval to the TGN and its
cytoplasmic tail has both an YXXj and a DXXLL motif.
These are motifs known to be involved in retromer-
dependent BACE-1 and sortilin retrieval to the TGN,
respectively [41,42]. APP also has a characteristic YXXj
sorting signal,
653YTSI
656, well positioned in the juxta-
membrane region of the cytoplasmic tail [60] that could
support both sorting at the TGN and TGN retrieval, as
recently observed for the YXXj motif in sortilin [42].
The
653YTSI
656 functional motif was first related to APP
endocytosis and post-TGN degradation [61-66], and
lately to AP-1-binding dependent APP basolateral sort-
ing in epithelial cells [43]. Further, protein cargo phos-
phorylation near or at the sorting motif could be a
positive modulator for its retrieval to the TGN. Indeed,
this occurs with CIMPR and BACE phosphorylation at
serine residues near their cytoplasmic sorting DXXLL
motif [41,67-69].
Protein phosphorylation is a major regulatory process,
and APP phosphorylation is known to alter its subcellu-
lar processing [16,46,60,64,65,70,71]. Although phos-
phoS655 APP molecules, within the APP
653YTSI
656
motif, have been reported in AD brains [65,72,73], a
clear physiological role for S655 phosphorylation, first
proposed to regulate APP sorting by Gandy et al. [51],
has not been forthcoming. We have recently observed
that APP phosphorylation at S655 enhances the protein
exit from the TGN to the PM and increased its cleavage
to asAPP [44]. Together with the data described here,
one can conclude that S655 phosphorylation is impor-
tant in regulating APP traffic from the TGN to the PM
and in recycling APP back to the TGN. In fact, as we
demonstrated, S655 phosphorylation has a key modula-
tory role in the sorting fate of endocytosed APP mole-
cules. The phosphomimetic APP
S655E, undergoes faster
and enhanced retrieval to the TGN (Fig. 5). Further
characterization of S655-dependent sorting at endo-
somes revealed that endocytosed APP
S655A was prefer-
entially targeted to the lysosomal default route (Fig. 4).
Similarly, retromer impairment has also been observed
to promote Sortilin and the Shiga toxin B-subunit tar-
geting to the lysosomal pathway [33,42]. The differential
sorting of the APP mutants at endosomes, for TGN
retrieval or lysosomal delivery, were reflected in the
half-lives of their APP-GFP mature forms (Fig. 4). This
confirmed a correlation between S655 phospho-state
dependent endosomal sorting and APP-GFP turnover
rates. The validation that S655 phosphorylation depen-
dent APP retrieval to the TGN occurred in a retromer-
mediated manner is confirmed by the VPS35 siRNA
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Page 14 of 21downregulation assays, where APP retrieval to the TGN
and APP half-life were significantly reduced (Fig. 8).
Importantly, we have observed a tendency for less Abeta
production for APP
S655E that may be a result of its
shorter time of residence in endosomes due to more
rapid retrieval to the TGN. This agrees with reports
inversely correlating components of this pathway with
Abeta production and AD [21,36-38,59,74].
From a molecular mechanistic perspective, APP S655
phosphorylation appears to lead to an increase in its
binding to sorting proteins, as occurs with the phos-
phorylation of BACE-1 and CI-MRP, wich enhance their
binding to GGA, a protein involved in this transport
[41,67-69,75,76]. In agreement with this, NMR analysis
of S655 phosphorylated APP was found to induce signif-
icant local conformational changes in the APP C-termi-
nus at and downstream the
653YTSI
656 motif [77].
Accordingly, we have observed more VPS35 immunor-
eactivity when VPS35 was co-immunoprecipitated with
the S655E mutant (Fig. 7c). Nonetheless, Wt and S655A
co-immunoprecipitated with VPS35 to similar extents,
suggesting that increased S655A targeting to lysosomes
involves not a default passive but a mediated active pro-
cess, involving lysosomal sorting molecules. Other
reports have indicated that retromer binding to cargo
proteins most likely occurs via its VPS10-containing
sorting receptor proteins, such as SorLA, and not via
direct binding of cargo to VPS35 [34]. Noticeably,
SorLA can bind GGA [39], and both can bind the cla-
thrin AP-1/2 adaptor proteins [27], and all are reported
to play roles in retrograde retrieval of cargo [21,27,75].
In light of our results, we speculate that S655 phosphor-
ylation enhances APP binding affinity for sorting pro-
teins such as SorLA [57] and/or the AP-1 adaptor,
which function to retrieve APP to the TGN in a com-
plex containing SorLA, AP-1, GGAs and the retromer.
Conclusions
For the first time we show that APP is retrieved from
the endosome to the TGN in a retromer-mediated path-
way, and that this process is positively regulated by APP
phosphorylation at its S655 residue. We have proved
that the phosphorylation state of S655 is determinant in
endocytic APP sorting to the TGN or lysosomes. S655
lies within the basolateral sorting APP motif, an impor-
tant motif for APP binding to targeting proteins, such as
SorLA and the retromer-related VPS35 protein. APP
phosphorylation-dependent targeting is highly relevant
from an AD therapeutic perspective. The pathogenesis
of sporadic AD may be caused, at least in part, by
impaired protein retrieval to the TGN [21,22,24,36,37].
Impairments of various cellular phosphorylation systems
have been widely reported in AD [78-80], and may like-
wise be relevant to the disease condition. Retrieval of
APP and BACE-1 to the TGN occur in a retromer- and
phosphorylation-dependent manner, and a failure in one
or both of these mechanisms would be predicted to
result in higher endosomal co-compartmentalization of
both proteins and enhanced amounts of generated
Abeta. Therefore, the retromer-mediated process and its
regulation by phosphorylation state of its cargo are both
potential pathogenic factors underlying AD, and possible
targets for future therapeutic strategies.
As further evidence for the key role of VPS10 domain
proteins in AD, Andersen et al [81] and Lane et al [82]
have recently demonstrated that SorLA modulation of
APP metabolism requires binding of the SorLA cyto-
plasmic tail to VPS35 [81], and that another VPS10-
domain protein, SorCS1, modulates coordinate risk of
Alzheimer’s disease and type 2 diabetes, apparently by
controlling levels of both SorLA and VPS35 [82]
Materials and methods
Antibodies
Primary monoclonal antibodies used were 22C11 (Chemi-
con) against the APP ectodomain, JL-8 (BD Biosciences)
for detection of the GFP moiety in APP-GFP proteins, the
1E8 monoclonal antibody (Nanotools, Germany) for Abeta
detection, and two anti-APP C-terminal antibodies (rabbit
anti-APP C-terminal, Zymed; rabbit APP C-terminal 369
antibody). Co-localization studies were carried out with
anti-Rab5 (early-endosomal marker) (StressGen Biorea-
gents) and anti-Rab7 (late-endosomal marker) (Cyto-
Signal) polyclonal rabbit antibodies, polyclonal goat
clathrin antibody (ICN Immunobiologicals), anti-cathepsin
D (lysosomal marker) monoclonal antibody (BD Bios-
ciences), and polyclonal anti-VPS35 C-20 goat antibody
(Santa Cruz Biotechnology). Immunoprecitipation and
detection of SorLA was carried out using anti-N-terminal
SorLA (BD transduction labs) or anti-SorLA C-terminal
antibody raised by Dr. James Lah; an anti-GFP antibody
(Sigma) was used in the IP controls. Secondary antibodies
used were Texas Red-conjugated IgGs, Alexa Fluor 350-
conjugated anti-rabbit IgGs, Alexa Fluor 568-conjugated
anti-goat IgGs (Molecular Probes) and FITC-conjugated
anti-rabbit IgGs (Calbiochem) for immunocytochemistry
analyses, and horseradish peroxidase-linked IgGs antibo-
dies (GE Healthcare) for enhanced chemiluminescence
(ECL) detection.
Wt and S655 Phosphomutants APP-GFP cDNAs
APP isoform 695 (APP695) cDNA was used as template
to generate S655 cDNA point mutations, namely Serine
655 to Alanine (S655A) or to Glutamate (S655E), using
site-directed mutagenesis [83]. These two amino acids,
due to their size and charge, mimic a constitutively
dephosphorylated and phosphorylated S655 residue,
respectively. To engineer the APP695-GFP cDNA
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phosphomutants APP695 cDNAs were removed by PCR
using specifically designed primers. The resultant frag-
ments were digested with endonucleases (AgeIa n d
NruI) and subcloned into the AgeI/SmaI restriction sites
of the GFP-encoding mammalian expression vector
(pEGFP-N1, Clontech) as N-terminal APP-GFP transla-
tional fusions. The nucleotide sequences of the APP695
phosphorylation cDNA point mutants and the open
reading frames were confirmed by DNA sequencing
(ABI PRISM 310 genetic Analyser, Applied Biosystems).
Co-localization of APP-GFP with endosomal markers
The endocytic pathway of the Wt APP-GFP protein was
first assayed using Texas-red conjugated transferrin
molecules (Molecular Probes) [84]. Monkey kidney
COS-7 cells were maintained with Dulbecco’s modified
Eagle’s medium (DMEM, Sigma) supplemented with
10% (v/v) fetal bovine serum (FBS, Gibco), 100 U/ml
penicillin/100 mg/ml streptomycin (p/s) and 3.7 g/l
NaHCO3 (complete DMEM) at 37°C and 5% CO2. COS-
7 cells were grown on 35 mm plates containing pre-
treated coverslips, with antibiotic/antimycotic (p/s)-free
DMEM until 90% confluent, and transiently transfected
with low levels of the APP-GFP cDNAs for 12 h. Trans-
fections were performed using the cationic lipid Lipofec-
tAMINE 2000 (Invitrogen Life technologies), according
to the supplier’s instructions. Transfected cells were
further exposed for 2:15 h to 50 μg/ml of the protein
synthesis inhibitor cycloheximide (CHX, Sigma), in p/s-
free DMEM. The experimental conditions for CHX drug
d o s ea n dt i m eo fe x p o s u r ew e r ep r e v i o u s l yo p t i m i z e d
[45,46]. Upon three washes with DMEM, cells were sub-
sequently incubated for 30 min at 37°C with p/s- and
FBS-free DMEM supplemented with 20 mM HEPES and
50 μg/ml CHX, to deplete endogenous transferrin. Med-
ium was replaced with medium containing 1 mg/ml
BSA and 100 nM Texas red-conjugated transferrin, and
cells incubated for a further 15 min at 37°C. The plates
were immediately cooled to 4°C and washed twice with
ice-cold PBS. Cells were methanol-permeabilized and
fixed with a 4% paraformaldehyde PBS solution. Addi-
tionally, two sets of Wt APP-GFP transfected cells were
incubated for 3 h with 50 μg/ml CHX, fixed and sub-
mitted to immunocytochemistry procedures using the
anti-Rab5 and anti-Rab7 antibodies diluted in a 3% BSA
PBS solution. Coverslips were mounted on microscope
slides with Fluoroguard Antifading Reagent (Bio-Rad)
and analyzed by epifluorescence microscopy and by con-
focal microscopy (quantitative analysis).
APP-GFP antibody uptake assays
COS-7 cells grown on polyornithine-coated glass cover-
slips were transiently transfected for 12 h with low levels
of Wt or S655 phosphomutant APP-GFP cDNAs, as
described above, and incubated with 50 μg/ml CHX for
2:30 h. An antibody uptake (AU) assay previously used
to characterize BACE-1 phosphorylation-dependent
TGN retrieval (Walter et al., 2001) was adapted. Briefly,
cells were washed twice with ice-cold PBS and incu-
b a t e df o r2 0m i no ni c e ,i nF B S - f r e eD M E Mc o n t a i n i n g
the 22C11 (anti-APP ectodomain) antibody. Upon three
washes with ice-cold PBS, cells were subsequently incu-
bated at 37°C in FBS-plus DMEM (10% FBS) for the
indicated time points (0, 15, or 30 min). At each time
point and after two washes with PBS and permeabiliza-
tion with methanol, cells were fixed in 4% paraformalde-
hyde, and processed for immunocytochemistry with
the antibodies indicated. To confirm endocytic Wt
APP-GFP targeting to the TGN/Golgi, cells were co-
transfected with a pECFP-Golgi construct (pEnhanced
Cyan Fluorecent Protein-Golgi, Clontech), which
encodes a fusion construct of ECFP and a sequence of
the human beta 1,4-GT (galactosyltransferase), targeting
it to the trans and medial region of the Golgi apparatus.
22C11 endocytic vesicles were visualized using an anti-
mouse Texas red-conjugated antibody. In the co-locali-
zation assays, 22C11 endocytic vesicles were visualized
using Alexa Fluor 350-conjugated antibody, and Rab5 or
clathrin were detected using an Alexa Fluor 568-conju-
gated antibody. For the retromer co-localization assay,
the endogenous VPS35 monomer was detected using an
Alexa Fluor 568-conjugated anti-goat antibody.
Immature and mature holo APP-GFP turnover rates
For a time-course analysis of APP-GFP turnover, COS-7
cells grown to 90% confluency were transiently trans-
fected with the APP-GFP cDNAs, as described above.
After 8 h, cells were divided into six-well plates contain-
ing 100 μg/ml polyornithine pre-treated glass coverslips,
and left to recover for 4 h. Cells were treated for differ-
ent times (0, 1, 2, 3 and 5 h) with 50 μg/ml CHX in
FBS- and p/s-free DMEM [45]a n dh a r v e s t e dw i t h1 %
SDS. The total protein content of the cellular lysates
was determined using a BCA kit (Pierce). Mass-normal-
ized samples were subjected to 6.5% SDS-PAGE in Tris-
Glycine buffer, and electrophoretically transferred onto
nitrocellulose membranes. Immunoblotting of the trans-
ferred proteins was performed by incubating membranes
O/N with primary antibodies after blocking non-specific
binding sites with non-fat dry milk in TBS-T (10 mM
Tris-HCl at pH 8.0, 150 mM NaCl, 0.5% Tween). Detec-
tion was achieved using horseradish peroxidase-linked
secondary antibodies and an ECL kit (GE Healthcare).
Wt and S655 mutants APP-GFP lysosomal targeting
COS-7 cells transiently expressing the Wt, S655A or
S655E APP-GFP cDNAs were incubated with CHX for
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described above. Upon fixing, cells were processed for
immunocytochemistry with the anti-cathepsin D anti-
body. Cathepsin D is a known lysosomal marker pre-
viously used in APP subcellular localization studies [53],
which is mainly sorted directly from the TGN to lyso-
somes. For the chloroquine assay, cells transiently
expressing S655A and S655E APP-GFP were exposed to
CHX (as described for the APP-GFP turnover rate) and
then treated with 50 μM of chloroquine (CQ), (Sigma).
This drug is a known inhibitor of lysosomal hydrolases
that act by neutralizing lysosomal pH. CQ retards
mature APP lysosomal degradation [85]. Cell lysates
were collected at the specified CHX time points and
subsequently analyzed by immunoblotting using the
anti-GFP antibody.
Secreted Abeta analysis
The medium of COS-7 cells grown on 60 mm plates
and transiently expressing the pEGFP vector or the
APP-GFP cDNAs was exchanged upon 12 h of transfec-
tion for 1.5 ml fresh p/s- and serum-free DMEM. After
a 3 h incubation period, this conditioned medium was
collected, centrifuged at 310 g for 5 min, and the resul-
tant supernatant immediately frozen in dry ice for Abeta
peptides analysis [86]. Media were immunoprecipitated
using 25 μl dynabeads (Dynal, Germany) coated with
1E8 mAb. Immunoprecipitates were separated on 12%
Bicine/Tris gel containing 8 M urea. Different Abeta
peptide species were detected by immunoblotting using
mAb 1E8 [87,88]. Total Abeta secretion was calculated
by densitometric analysis of all Abeta peptide bands,
corrected for holo APP-GFP transfection levels and
expressed as fold-increases of Wt total Abeta.
Immunoprecipitation of APP, VPS35 and SorLA
COS-7 cells, non-transfected or transfected with the
APP-GFP cDNAs for 24 h by means of Lipofectamine,
were washed with PBS and collected with a scraper in
lysis buffer [50 mM TrisHCl ph 8.0, 100 mM NaCl, 1
mM EDTA, 1% CHAPS, containing 0.2 mM PMSF and
a protease inhibitor cocktail (Sigma)] and briefly soni-
cated on ice. Protein mass normalized aliquots were
pre-cleared for 1 h with 25 μl protein G sepharose (for
VPS35 IP; GE Healthcare) or anti-mouse IgGs agarose
beads (for 22C11 or JL-8 IPs; Sigma). Following removal
of the beads, lysates were incubated overnight at 4°C
with the appropriate primary antibodies, anti-GFP JL-8
(1:200) or 22C11 (1:20) and VPS35 (1:20), and further
incubated for 3 h with 50 μl of the appropriated beads
pre-cleared for 1 h with 5% BSA. HEK293T cells were
transfected with SorLA DNA, APP695 and EGFP using
Lipod293 reagent (SignaGen). Cells were harvested 48 h
following transfection, washed with PBS and lysed in
lysis buffer [50 mM TrisHCl ph 7.5, 100 mM NaCl, 1
mM EDTA, 1% Nonidet P-40, 0.2 mM PMSF, 0.2 mM
Na3VO4,5 0m MN a F ,1 0m Ms o d i u mp y r o p h o s p h a t e ,
containing a protease inhibitor cocktail (Roche)]. For
Immunoprecipitation, the lysates were pre-cleared with
the appropriate control IgG and 20 μlo fp r o t e i nA / G
agarose (Santa Cruz) for 30 min. Following removal of
A/G agarose beads, lysates were incubated with 1 μgo f
the appropriate primary antibody (anti-SorLA BD trans-
duction labs, or APP C-terminal antibody, 369) or pre-
immune serum (negative control) overnight at 4°C, fol-
lowed by a further 3 h with protein A/G agarose beads.
Following the 3 h incubation period, beads were sub-
sequently washed 4 times with washing buffer (lysis buf-
fer minus CHAPS) or lysis buffer, resuspended in SDS
sample buffer and boiled at 95°C for 5 min prior to ana-
lysis by SDS PAGE. Western blots were performed
using anti-APP (22C11 and 369), anti-VPS35, anti-
SorLA (C-terminal antibody) and anti-GFP antibodies.
VPS35 siRNAs antibody uptake and turnover assays
VPS35 expression was transiently down-regulated using
Silencer Select Pre-designed siRNAs (Applied Biosys-
tems/Ambion) against human VPS35 mRNA (GenBank:
NM_018206.4, 99% homologous to monkey VPS35
mRNA): s31374: 5’CCACGUUGAUUCAAGAUCAtt;
s31375: 5’CCAUGGAUUUUGUACUGCUtt3’; s31376:
5’GUCUGUUUCUUGAAAUUAtt3’.T oo p t i m i z et h e
siRNA conditions, 5x10
4 COS 7 cells were plated on a
24-well plate, 24 hours before being co-transfected with
0.5 μg N1 EGFP cDNA and 0, 1, 5, 10 and 20 nM of each
VPS35 siRNA duplex by means of TurboFect siRNA
Transfection Reagent (Fermentas Life Science), following
the manufactures’ instructions. Down-regulation of
VPS35 expression was monitored in cells lysates upon 24
h (and 48 h, data not shown) of transfection. To perform
t h ea n t i b o d yu p t a k ea n dt u r n o v e re x p e r i m e n t s ,5 x 1 0
4
COS 7 cells were plated on 24-well plates 24 hours before
being co-transfected with 0.5 μg S655E APP-GFP cDNA
and 5 nM of each VPS35 siRNA duplex. Upon 24 hours
of transfection, cells were incubated in 50 μg/ml CHX for
several time points (0, 1, 2, 3, and 5 h), after which they
were processed for immunoblotting procedures as
described above (holo APP-GFP turnover rate assay). A
subset of S655E/siRNAs co-transfected cells, previously
grown on polyornithine-coated glass coverslips, was sub-
jected to the above described 22C11 antibody uptake
assay upon 2:30 h in 50 μg/ml CHX, with endocytosis
being allowed to occur for 15 min at 37°C.
Protein band quantification and statistical analysis
Autoradiograms were scanned in a GS-710 calibrated
imaging densitometer (Bio-Rad) and protein bands
quantified using the Quantity One densitometry
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of at least three independent experiments. Statistical sig-
nificance analysis was conducted by one way analysis of
variance (ANOVA) followed by the Tukey-Kramer test,
with the level of statistical significance set at p < 0.05.
For the CQ and VPS35 siRNAs APP-GFP turnover rate
assays, the two-sided Student t test was used, with sta-
tistical significance set at p ≤ 0.05.
Image acquisition and quantification
Epifluorescence microscopy was carried out using an
Olympus IX-81 motorized inverted microscope equipped
with Olympus LCPlanFl 20 ×/0.40 and 60 ×/0.70 objec-
tive lens. Photographs were taken at 18°C with a Digital
CCD monochrome camera F-View II (Soft Imaging Sys-
tem) and processed with the AnalySIS software (Soft
Imaging System). For confocal microscopy, images were
acquired in a LSM 510 META confocal microscope
(Zeiss) using an Argon laser line of 488 nm (APP-GFP
channel), a 561 nm DPSS laser (Texas red and Alexa
Fluor 568 labels channel), and a Diode 405-430 laser
(ECFP and Alexa Fluor 350 labels channel). Quantitative
correlation analysis (e.g., [89,90]), was carried out with
the Zeiss LSM 510 4.0 software, using images of all cells
populations (endogenous APP observations) or images of
delimited single cells (APP-GFP transfected cells). For
co-localization of Wt APP-GFP with protein markers of
the endocytic pathway, the co-localization coefficients
were determined as the percentage of APP-GFP/Trans-
ferrin, APP-GFP/Rab 5 and APP-GFP/Rab 7 co-localizing
pixels relatively to the number of pixels in the APP-GFP
channel. For lysosomal targeting, the co-localization coef-
ficients were determined as the percentage of APP-GFP/
cathepsin D co-localizing pixels relatively to the number
of pixels in the APP-GFP channel. For endocytosed APP-
GFP targeted to the TGN, the co-localization coefficients
were determined as the percentage of Texas red-22C11/
APP-GFP co-localizing pixels at the Golgi relatively to
t h en u m b e ro fp i x e l si nt h eT e x a sr e d - 2 2 C 1 1c h a n n e l .
For retromer co-localization, the co-localization coeffi-
cients were determined as the percentage of Alexa350-
AU 22C11 or APP-GFP/VPS35 co-localizing pixels rela-
tively to the number of pixels in the Alexa350-AU 22C11
or APP-GFP channels, respectively.
Additional material
Additional file 1: Retrieval of clathrin/APP-GFP endocytic vesicles
from endosomes to the TGN is hindered at 19.5°C. Wt APP-GFP
expressing COS-7 cells were subject to the previous 22C11 uptake assay
(Alexa350 blue staining). Following 15 min at 19.5°C, Clathrin/APP-GFP
endocytic vesicles can still be observed, with a good juxtaposed co-
localization. Further, these vesicles appear more dispersed and the
number of tubulating vesicles is clearly diminished. ROI, region of
interest, 2.0-fold magnified. Bar, 10 μm.
Additional file 2: Redistribution of APP and VPS35 proteins upon
exposure of HeLa cells to PDBu. HeLa cells were cultured in MEM
medium supplemented with Glutamax and 10% FBS (Gibco BRL), and
exposed for two hours to 1 μM PDBu, a known PKC inducer. Cells were
fixed and subjected to immunocytochemistry procedures using an anti-
APP C-terminus antibody (green FITC secondary labeling) and an
antibody against the retromer component VPS35 (red Alexa Fluor 568
secondary labeling). Cell nuclei were stained with DAPI (blue
fluorescence). Redistributions of the protein populations, from a more
cytoplasmic diffuse morphology to a more perinuclear Golgi-like
concentrated pattern (arrows), can be observed in response to PDBu. Bar,
10 μm.
Additional file 3: Representative profile of APP-GFP C-terminal
peptides with time in CHX. Immunoblot analysis (12% SDS-PAGE) of Wt
APP-GFP transfected COS-7 cells lysates using the anti-GFP JL-8 antibody.
The bands around and below ~37 kDa correspond to APP-GFP C-
terminal peptides (CTPs-GFP), positive for the anti-APP C-terminal
antibody and negative for 22C11 against APP N-terminus (data not
shown). S655A and S655E mutants render similar CTPs-GFP profiles when
in CHX (data not shown). Top and bottom panels correspond to
cropped areas of the same autoradiogram, and therefore have the same
exposure time conditions.
Additional file 4: Omission of cell permeabilization in the 22C11
uptake assay impairs visualization of APP-GFP endocytic vesicles.
COS-7 cells expressing the Wt, S655A and S655E APP-GFP proteins were
pre-incubated at 4°C to inhibit endocytosis (0 min). Addition of the
22C11 anti-APP ectodomain antibody ("APP N-term”), allowed for the
labelling of APP-GFP proteins at the cell surface. At 0, 15, and 30 min of
incubation at 37°C, cells were subjected to immunocytochemistry
procedures with a Texas red secondary antibody without previous
permeabilization. Clear endocytic vesicles (e.g. as observed in Fig. 3 and
5) were no longer visible when cell permeabilization is omitted. Instead,
a surface dot-like staining could be observed for the 22C11 antibody (0
min), which decreased with time of 37°C incubation, in accordance with
continuous 22C11/APP-GFP surface clearance by endocytosis. ROI, region
of interest. Bar, 10 μm.
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